Evofem posted $13.4 million in net sales of Phexxi for the first nine months of 2023;
Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.